BioPharma Dive August 12, 2024
The funding will support research on dual-acting drugs that use protein interactions to snuff out essential functions in tumor cells.
Halda Therapeutics, a startup using new cancer-fighting technology developed by serial biotechnology entrepreneur Craig Crews, has raised $126 million in new funding to advance experimental drugs into human testing for prostate and breast cancers, the company said Monday.
The Series B round extension brings to $202 million the total Halda has raised in support of a drug technology it calls RIPTAC, which uses a dual-acting small molecule drug to spur an interaction between proteins that kills tumor cells. Discovered in Crews’ Yale University laboratories, the RIPTAC technology builds on research that involves “gluing” proteins together inside tumor cells to tag...
Today's Sponsors
Today's Sponsor